DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States.
Flawless balance sheet with limited growth.
Share Price & News
How has DermTech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DMTK's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how DMTK performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how DMTK performed against the US Market.
Price Volatility Vs. Market
How volatile is DermTech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is DermTech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DMTK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DMTK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DMTK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: DMTK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DMTK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DMTK is good value based on its PB Ratio (3x) compared to the US Biotechs industry average (3.8x).
How is DermTech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DMTK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DMTK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DMTK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DMTK's revenue (95.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: DMTK's revenue (95.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DMTK's Return on Equity is forecast to be high in 3 years time
How has DermTech performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: DMTK is currently unprofitable.
Growing Profit Margin: DMTK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DMTK's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare DMTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DMTK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: DMTK has a negative Return on Equity (-32.32%), as it is currently unprofitable.
How is DermTech's financial position?
Financial Position Analysis
Short Term Liabilities: DMTK's short term assets ($70.1M) exceed its short term liabilities ($5.3M).
Long Term Liabilities: DMTK has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DMTK is debt free.
Reducing Debt: DMTK has no debt compared to 5 years ago when its debt to equity ratio was 22%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DMTK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: DMTK has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 20.1% each year.
What is DermTech's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DMTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DMTK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DMTK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DMTK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DMTK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Dobak (53yo)
Dr. John D. Dobak, M.D. has been the Chief Executive Officer and President of DermTech, Inc. since June 26, 2012. Dr. Dobak is the Co-Founder of Post-Hypothermia Corporation and serves as its Chief Executi ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD1.52M) is about average for companies of similar size in the US market ($USD1.42M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
|Chief Medical Officer||3.33yrs||US$480.83k||0.48% $959.3k|
|Chief Commercial Officer||1.33yrs||US$846.18k||0.91% $1.8m|
|CFO, Treasurer & Secretary||0.67yr||no data||no data|
|Chief Operating Officer||0.58yr||no data||0.74% $1.5m|
|Chief Scientific Officer||3.33yrs||no data||0.18% $371.4k|
|Vice President of Marketing||no data||no data||no data|
|Senior Vice President of Payer Access||1.33yrs||no data||no data|
Experienced Management: DMTK's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Independent Director||7.33yrs||US$103.02k||0.26% $519.2k|
|Independent Director||2.75yrs||US$102.00k||0.20% $393.9k|
|Independent Chairman of the Board||0.75yr||US$108.94k||0.26% $525.2k|
|Independent Director||no data||US$97.75k||8.77% $17.6m|
|Independent Director||13.33yrs||US$47.63k||1.16% $2.3m|
|Independent Director||2yrs||US$89.69k||0.13% $262.6k|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||2.58yrs||no data||no data|
|Member of Scientific Advisory Board||1.5yrs||no data||no data|
Experienced Board: DMTK's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: DMTK only recently listed within the past 12 months.
DermTech, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: DermTech, Inc.
- Ticker: DMTK
- Exchange: NasdaqCM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$200.950m
- Shares outstanding: 14.91m
- Website: https://www.dermtech.com
Number of Employees
- DermTech, Inc.
- 11099 North Torrey Pines Road
- Suite 100
- La Jolla
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DMTK||NasdaqCM (Nasdaq Capital Market)||Yes||New Common Stock||US||USD||Aug 2019|
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/26 04:38|
|End of Day Share Price||2020/05/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.